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Infection After Acute Ischemic Stroke
A Manifestation of Brain-Induced Immunodepression
A´ ngel Chamorro, MD, PhD; Xabier Urra, MD; Anna M. Planas, PhD
Background and Purpose—Infection after experimental focal ischemia may result from brain-induced immunodepression,
but it is unsettled whether a similar syndrome occurs in human stroke.
Summary of Review—Many patients develop infections shortly after acute stroke regardless of optimal management.
Mortality is higher in these patients and the severity of stroke is the strongest determinant of the infectious risk.
However, it is controversial whether infections promote neurological worsening or alternatively represent a marker of
severe disease. The brain and the immune system are functionally linked through neural and humoral pathways, and
decreased immune competence with higher incidence of infections has been demonstrated in several acute neurological
conditions. In experimental brain ischemia, infections are associated with the activation of the autonomous nervous
system and neuroendocrine pathways, which increase the strength of anti-inflammatory signals. A strong cytokine-
mediated anti-inflammatory response was recently observed in stroke patients at higher risk of infection, although
infection could not demonstrate an independent association with the progression of the symptoms.
Conclusions—The appearance of infection in patients with acute stroke obeys in part to immunological mechanisms
triggered by acute brain injury. An excessive anti-inflammatory response is a key facilitating factor for the development
of infection, and it is likely that this immunological response represents an adaptive mechanism to brain ischemia.
Contrarily, it is unclear whether infection contributes independently to poor outcome in human stroke. Overall, a better
understanding of the cross-talk between the brain and the immune system might lead to more effective therapies in
patients with acute stroke. (Stroke. 2007;38:1097-1103.)
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Evidence is accumulating in support of a role for inflam-matory, innate immune and adaptive immune mecha-
nisms in many facets of vascular disease.1,2 Numerous studies
and recent reviews have addressed the role of infection as a
risk factor of stroke,3,4,5,6,7 and the main clinical traits,8,9 and
immunohematologic characteristics of strokes preceded by
recent infection have also been described.10,11,12 However, the
mechanisms and neurological consequences of infections
complicating the clinical course of acute stroke have received
less attention. A growing body of evidence currently indicates
that the central nervous system and the immune system are 2
supersystems closely linked13 and that this functional inter-
action could pave the way to the appearance of immunolog-
ical manifestations as the result of central nervous system
injury, and vice versa. In the same line, the emergence of
systemic infection after acute brain damage could be a
symptom of central nervous system–mediated decrease of
immune competence, as described in patients with brain
tumors, epilepsy, or traumatic brain injury.14,15 This review
brings up to date the cross-talk between the central nervous
system and the immune system in patients with acute stroke
and how this interaction affects their clinical course. The
mechanisms and clinical consequences of poststroke infec-
tion are emphasized because a better understanding of these
processes is essential to consider in the future the application
of immunomodulatory therapies in patients with acute brain
ischemia.
Infection After Acute Stroke: Magnitude of
the Problem
Autopsy series indicate that death within the first week after
stroke is attributable primarily to the direct effects of brain
damage, such as brain edema with transtentorial herniation.16
Subsequent mortality is attributable in autopsy,16 and
population-based studies,17 to medical complications such as
infection. The frequency and nature of the medical compli-
cations that follow acute stroke have been addressed in
several clinical studies18–27using a wide range of different
designs, methods of patient selection, diagnostic criteria,
timing of assessment, or duration of follow-up, as shown in
the Table. Hence, it is not surprising that the reported
incidence of specific medical complications varies from 40%
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to 96% of patients, with the highest frequency reported in
prospective studies.22 The most common medical conditions
encountered in these studies include urinary tract infections,
venous thrombi, pneumonias, joint and soft-tissue pain,
sepsis, and falls.28 Most poststroke infections involve the
respiratory or urinary tracts, although chest infections prevail
during the first few days after stroke.20,29 Pneumonia is
reported to complicate the course of 7% to 22% of the stroke
patients,21,22,23,30 and dysphagia and aspiration are the most
commonly incriminated factors.31,32
Is Infection a Cause of Worsening
Stroke? Uncertain
The proportion of patients experiencing infections is higher in
patients with severe stroke29,33,26 unlike other stroke compli-
cations such as falls, depression or pain.23 Infections can
facilitate electrolytic unbalance, hypoxia, and fever, which
could theoretically impair neuronal survival within the ische-
mic penumbra.34 Fever may increase the cerebral metabolic
demands,35 change the blood-brain barrier permeability, and
promote acidosis and release of excitatory amino acids.36
Entry of bacteria and lypopolisaccharide into the bloodstream
also favors thrombosis through tumor necrosis factor
(TNF)- release,37 activation of the tissue factor–mediated
extrinsic pathway of blood coagulation,38 reduction of throm-
bomodulin (anticoagulant), and inhibition of the fibrinolytic
system.39 With few exceptions,40 subfebrile temperatures
(37.5°C to 39°C) and fever (39°C) during the first days of
stroke are associated with larger infarct volumes, higher
mortality, and poorer functional outcome.41,42 However, the
support to infection as an independent cause of stroke
worsening is controversial.29,43,44 Only few studies29,43 ac-
counted for the critical effect of the initial severity of stroke,
and in some studies,22 the recognition of stroke worsening
relied on the neurological scale used for assessment. Recent
prospective studies did not find an independent association
between infection and stroke worsening in multivariate anal-
ysis.29,44 It has been argued that the inclusion of soft end
points, such as acute bronchitis, could have minimized the
clinical relevance of poststroke infection45 although acute
bronchitis in the elderly—an age group representative of the
stroke population—conveys a similar risk of death than
pneumonia: 10% and 8%, respectively.46 Further, acute re-
spiratory infection with “normal” chest x-rays may indicate
pneumonia in about 30% of the cases, if a high resolution
lung tomography is performed.47
Could Infection Be a Manifestation of
Stroke-Induced Immunodepression in Human
Stroke? Most Likely
The appearance of infections after acute stroke could be
related to mechanisms other than the application of invasive
maneuvers, decreased consciousness, or abnormal brain stem
reflexes. Thus, predominance of infections during the phase
of maximal neurological impairment (first 3 days),48 and
comparable incidence of infection in conventional wards,
neurological wards, intensive care units, or stroke units
suggest that infection might also be explained by stroke-
induced immunological mechanisms. In addition to the sup-
port of this proposition is the rich bidirectional communica-
tion existing between the central nervous system and the
immune system.13,49 As it is schematically represented in
Figure 1, the central nervous system modulates the activity of
the immune system through complex humoral and neural
pathways that include the hypothalamic pituitary adrenal
(HPA) axis, the vagus nerve, and the sympathetic nervous
system.13
Humoral Pathways for Brain to Immune
System Communication
The HPA axis is a major part of the neuroendocrine system
with important functions in health and disease, and with key
elements located in the paraventricular nucleus (PVN) of the
hypothalamus, the anterior lobe of the pituitary gland, and the
Major Studies Analyzing the Infection Rate in Stroke Patients
Authors
Reference
No. Design Stroke Subtypes
Sample
Size
Infection
Rate, %
Follow-Up,
days
Davenport et al 21 Retrospective Ischemic/Hemorrhagic 597 35 37
Johnston et al 22 Retrospective Ischemic 279 8* 90
Langhorne et al 23 Prospective Ischemic/Hemorrhagic 311 65 35
Grau et al 24 Prospective Ischemic 119 10† 2
Heuschmann et al 25 Retrospective Ischemic 13 440 6‡ 10.6
Hamidon et al 26 Prospective Ischemic 163 16 3
Hilker et al 27 Prospective Ischemic/Hemorrhagic§ 124 15‡ 3
Weimar et al 28 Retrospective Ischemic 3866 13.7 7
Vargas et al 29 Prospective Ischemic/Hemorrhagic 229 27 7
Katzan et al 30 Retrospective Ischemic/Hemorrhagic 14 293 7‡ 30
Smithard et al 31 Prospective Ischemic/Hemorrhagic 121 24‡ 7
*Only serious complications were reported (those that were immediately life-threatening, prolonged or resulted in hospitalization,
or resulted in death).
†This figure excludes additional 11% of patients in whom infection was considered to precede ischemia.
‡Pneumonia only.
§Patients included in a neurological intensive care unit.
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cortices of the adrenal gland. Cytokines such as interleukin
(IL)-1, TNF-, and IL-6, secreted by cells in different
tissues and organs including the brain50 can stimulate special-
ized neurons in the PVN to synthesize corticotropin-releasing
factor.51 Blood-borne cytokines derived from white blood
cells may also reach the PVN through activation of specific
carriers, binding to endothelial receptors that mediate the
production of diffusible mediators, such as prostaglandins or
NO, or through anatomical structures lacking blood-brain
barrier, like the organum vascularis of the lamina terminals,
or the area postrema.50,52 Once released into the pituitary
portal blood system, corticotropin-releasing factor interacts
within the anterior pituitary with a specific G protein–
coupled receptor (corticotrophin-releasing factor-F1) facili-
tating the secretion of adrenocorticotropin hormone precursor
peptide proopiomelanocortin, and adrenocorticotropin hor-
mone (ACTH).53 Secondarily, ACTH induces the secretion of
glucocorticoids from the zona fasciculata of the adrenal
cortex which suppress the production of pro-inflammatory
mediators, including IL-1, IL-11, IL-12, interferon-,
TNF-, chemokines (IL-8), prostaglandins and NO.54 Glu-
cocorticoids also facilitate the release of anti-inflammatory
mediators such as IL-4, IL-10 and transforming growth
factor-,55 and have strong antiproliferative properties, and
apoptotic effects in immune cells.56 In the end, cytokines can
activate the release of glucocorticoids, which in turn suppress
further cytokine synthesis in a classic negative feedback
loop.57
The Cholinergic Neural Pathway
The PVN is functionally linked with autonomic centers such
as the nucleus of the solitary tract (NST) or the locus
coeruleus.58 The PNV-NST pathway allows the synchroniza-
tion of neuroendocrine responses with the cholinergic anti-
inflammatory pathway to suppress the peripheral release of
cytokines through macrophage nicotinic receptors.59 Indeed,
direct electrical stimulation of the efferent vagus nerve
inhibits the synthesis of TNF- in different organs during
experimental endotoxemia and in animals subjected to
ischemia-reperfusion.60
The Adrenergic Pathway
to Immunodepression
The sympathetic nervous system also plays a crucial role
in the communication between neural and immune structures.
The sympathetic division originates in brain stem nuclei such
as the locus coeruleus and the rostral ventrolateral medulla
that give rise to preganglionic cholinergic efferent fibers.
Postganglionic sympathetic fibers run from paravertebral or
prevertebral ganglia to release norepinephrine in different
tissues, and parallel increases in brain norepinephrine con-
centrations and plasma corticosterone61 support the existence
of a reverberatory feedback loop between the HPA and the
sympathetic nervous system.62 Activation of the locus coer-
uleus leads to release of norepinephrine from an extraordi-
narily dense network of neurons throughout the brain, and
from peripheral organs, resulting in enhanced arousal and
vigilance, increased heart rate, respiratory rate, vascular tone,
and gastrointestinal motility, but also in the induction of
pronounced immunological changes.52,63 The latter effects
mainly result from the inhibition of T helper (h) type 1
pro-inflammatory activities, giving way to the predominance
of Th type 2 anti-inflammatory activities.13
The Adrenal Medullary Gland
The chromaffin cells of the adrenal medulla are homologs of
the sympathetic ganglia derived from the neural crest,64 and
activation of cholinergic preganglionic sympathetic neurons
innervating these cells may lead to increased release of
catecholamines in the bloodstream, where they act as hor-
mones. Unlike the adrenergic nerves which preferentially
release norepinephrine, the adrenomedullar gland secretes
epinephrine at a ratio of 4:1 over norepinephrine. Catechol-
amines from the adrenal medulla are metabolized by
catechol-O-methyl-transferase (COMT) and monoamine ox-
idase, respectively, and metanephrine and normetanephrine,
are the main products mediated by COMT.65 Because sym-
pathetic nerves do not contain COMT, metanephrine and
normetanephrine mirror the catecholaminergic activity from
non-neuronal sources. Indeed, 91% of plasma metanephrine
and up to 40% of normetanephrine are produced under stress
conditions within the adrenal medullary gland.66 In clinical
situations such as hypoglycemia, hemorrhagic hypotension,
asphyxiation, circulatory collapse, and distress, higher plasma
concentrations of epinephrine (adrenal gland) than norepi-
nephrine (terminal nerves) have been reported, suggesting
greater adrenomedullary hormonal than sympathetic neuronal
activation.67 However, as further discussed below, the adrenal
Figure 1. Schematic representation of the main communication
pathways between the central nervous system and the immune
system. ACTH indicates adrenocorticotropin hormone; CRF,
corticotropin releasing factor; E, epinephrine; GCs, glucocorti-
coids; HT, hypothalamus; LC, locus coeruleus; MN, metaneph-
rine; NE, norepinephrine; NMN, normetanephrine; NST, nucleus
of the solitary tract.
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medullary gland has received little attention in clinical and
experimental studies of acute stroke.
The Lymphoid Organs Are Also Wired
The neural control of the immune system is further facilitated
by the rich supply of sympathetic nerve fibers to primary
(thymus and bone marrow) and secondary (spleen, lymph
nodes, and tissues) lymphoid organs.68 Likewise, with the
exception of Th type 2 cells,69 virtually all immune cells
express adrenoreceptors, including lymphocytes, granulo-
cytes, monocytes, macrophages, and natural killer cells.63,70
Catecholamines released within the microenvironment of
immune cells located in lymphoid organs increase their
intracellular levels of cAMP and activate protein kinase A.71
The net result is the inhibition of TNF-, IL-1, IL-12,
interferon-, and nitric oxide production, and the increased
production of IL-6 and IL-10 by the immune cells. Elevation
of central sympathetic outflow also induces a local release of
norepinephrine within the bone marrow,72 and this affects in
vivo myelopoiesis and erythropoiesis,73 because the produc-
tion of granulocytes and macrophages is under a sympathetic
inhibitory tone, whereas lymphocyte74 and erythrocyte73 for-
mation require adrenergic stimulation.
Immunological Changes After Acute Brain
Ischemia: Experimental and Clinical Studies
In patients with acute stroke, increased75,76,77,78 or abnormally
low78,79 secretion of ACTH and cortisol are associated with
larger infarctions, poorer functional outcome, and increased
mortality, indicating that both extremes of the HPA axis
response may be deleterious. Patients with increased cortisol
may have a strong inflammatory response, with increased
temperature, fibrinogen, white blood cell counts,
-thromboglobulin, and IL-6 levels.79,80 High cortisol has
also been associated in some studies,81 but not in others,81,82
with higher catecholamine excretion, and frontal lobe, or
insular infarctions.83,84 Unfortunately, the rate of infection
and immune competence were not described in the patients
included in these studies.
In brain ischemic mice, stroke induces a long-lasting
depression of the cell-mediated immunity, including mono-
cyte deactivation, lymphopenia, and a Th1/Th2 shift associ-
ated with spontaneous bacteremia and pneumonia.85 In mice,
focal cerebral ischemia also reduces spleen cellularity and
response to mitogens,86 and results in a rapid and widespread
production of pro-inflammatory factors by splenocytes in
relation to adrenergic signaling.87 Propranolol prevents these
infections,85 emphasizing the relevance of a catecholamine-
mediated immune defect for impaired antibacterial defenses.
Lypopolisaccharide preconditioning has also shown to induce
significant neuroprotection against middle cerebral artery
occlusion, suppressing both neutrophil infiltration into the
brain and microglia/macrophage activation in the ischemic
hemisphere, and monocyte activation in the peripheral
blood.88
In patients, reported defects in immune function after
stroke include reduced peripheral blood lymphocyte counts
and impaired T- and natural killer cell activity, and reduced
mitogen-induced cytokine production and proliferation in
vitro.89,90 One small study91 found a higher incidence of
severe infections after left hemisphere infarctions although in
the larger ESPIAS trial the incidence of infection was not
lateralized,48 in agreement with observations in ischemic
rats.92 In this clinical trial, levofloxacin was not able to
Figure 2. Temporal course of cytokine lev-
els in plasma in patients with stroke-
associated infection (SAI) within 7 days of
clinical onset as compared with patients
without stroke-associated infection (NO-
SAI). A, IL-6; B, IL-10; C, TNF-; D, IL-10
to TNF- ratio.
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prevent the incidence of infection in patients with nonseptic
acute stroke.48 However, antibiotic therapy with moxifloxacin
prevented infection in ischemic mice,93 and ongoing studies
of antibiotic prophylaxis in stroke patients might indicate that
the efficacy of this approach relies on patient selection,
differences in antibiotics, or the administration regime.94
The longitudinal changes of plasma cytokines and circulating
white blood cells were also assessed in the patients included in
the ESPIAS trial.48,95 As described in Figure 2, patients with
stroke have a rapid increase of circulating cytokines in plasma,
with a low ratio of pro-inflammatory TNF- to anti-
inflammatory IL-10 preceding the appearance of infection,95 in
agreement with experimental data,96,97 and clinical studies of
patients with fatal community-acquired infection.98 These obser-
vations caution about the potential risks of pro-inflammatory
cytokine inhibition in patients with sepsis. Monocytes, neutro-
phils, and total counts of white blood cells are also increased
before infections, as shown in Figure 3. Recently, poststroke
infection has also been associated with higher admission levels
of metanephrine, emphasizing the relevance of sympathoad-
renomedullary function for immune competence.99 Indeed, in
human adrenals, the medullary tissue (catecholamines) and the
cortex (glucocorticoids) are extensively intermingled, and this
anatomical disposition allows important intraadrenal paracrine
interactions.100
Conclusions
As previously described in experimental conditions, accumu-
lating clinical evidence also suggests that acute stroke may
induce significant immunological changes that could facili-
tate the appearance of infection in human stroke. Whereas
infections predominate in patients with severe stroke who
frequently may undergo invasive maneuvers facilitating the
entry of pathogens, recent clinical studies underscore the
relevance of immunological changes such as an excessive
counter-inflammatory cytokine response. These cytokines
may come from injured brain cells or from peripheral organs,
including circulating white blood cells—mostly monocytes
and neutrophils—which are significantly increased before
clinical signs of infection. The autonomous nervous system,
the HPA axis, lymphoid organs and adrenal medulla provide
reverberating pathways for rich neuroimmunological interac-
tions. Indeed, the strength of adrenomedullary activity has
recently been proved to be associated to the risk of infection
in patients with acute stroke. The support for an independent
causal relationship between infections and additional ische-
mic brain damage is challenged by recent data. Yet, the
existence of a stroke-induced immunodepression syndrome
might be an adaptive mechanism to brain ischemia although
further research will be required to unravel the clinical
consequences of these immunological changes. Hopefully, a
better understanding of the complex cross-talk between the
central nervous system and the immune system might lead in
the future to more effective stroke therapies.
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